DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: PROHANCE

Summary for Tradename: PROHANCE

Patents:1
Applicants:1
NDAs:2
Suppliers: see list1
drug
patent expirations by year for
 PROHANCE

Pharmacology for Tradename: PROHANCE

Clinical Trials for: PROHANCE

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Status: Completed Condition: Brain Metastases

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Status: Completed Condition: Diagnostic Imaging; Central Nervous System Diseases

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Status: Completed Condition: Brain Disease

Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
Status: Active, not recruiting Condition: Renal Insufficiency

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Completed Condition: Coronary Artery Disease; Type 1 Diabetes Mellitus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco
PROHANCE
gadoteridol
INJECTABLE;INJECTION020131Nov 16, 1992RXYes5,846,519<disabled><disabled>
Bracco
PROHANCE MULTIPACK
gadoteridol
INJECTABLE;INJECTION021489Oct 9, 2003RXYes5,846,519<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc